LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
44 hedge funds and large institutions have $86M invested in LogicBio Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 8 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
10% more funds holding
Funds holding: 40 → 44 (+4)
38% less capital invested
Capital invested by funds: $138M → $86M (-$52.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$904K |
| 2 |
Morgan Stanley
New York
|
+$357K |
| 3 |
BlackRock
New York
|
+$345K |
| 4 |
FT
Fiduciary Trust
Boston,
Massachusetts
|
+$280K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$171K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$8.1M |
| 2 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$1.92M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.19M |
| 4 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$211K |
| 5 |
JG
Jefferies Group
New York
|
-$115K |
LOGC Hedge Fund Activity: Q4 2019 in Review
44 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q4 2019, worth a combined $86M — down 38% from $138M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LOGC positions and 3 closed out — a net gain of 4 holders — while 18 added to existing stakes and 8 trimmed.
The largest buyer was Samlyn Capital, adding an estimated $904K. The largest seller was Redmile Group, exiting entirely with an estimated $8.1M sold.
- 44 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q4 2019, up from 40 in Q3 2019.
- Funds reported $86M of LogicBio Therapeutics, Inc. Common Stock stock for Q4 2019, down 38% quarter-over-quarter.
- 7 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q4 2019 and 3 closed out, a net change of +4 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q4 2019 was Samlyn Capital, an estimated $904K added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q4 2019 was Redmile Group, an estimated $8.1M sold.
Based on aggregated 13F filings for Q4 2019.